evaluation of the neuroprotective effect of …ginmu.naramed-u.ac.jp › dspace › bitstream ›...
TRANSCRIPT
1
Evaluation of the neuroprotective effect of minocycline in a rabbit spinal cord
ischemia model
Keisuke Watanabe, MD*, Masahiko Kawaguchi, MD*, Kazuhiko Kitagawa, MD*,
Satoki Inoue, MD*, Noboru Konishi, MD+, and Hitoshi Furuya, MD*
Department of *Anesthesiology and +Pathology,
Nara Medical University, Kashihara, Nara,Japan.
Corresponding Author: Keisuke Watanabe, MD
Department of Anesthesiology
Nara Medical University, Nara, Japan
840 Shijo-cho, Kashihara, Nara 634-8522, Japan
Tel: +81-744-22-3051, Fax: +81-744-23-9741
E-mail: [email protected]
Conflict of Interest: There are no conflicts of interest to disclose.
Financial Support: Supported by Grant-in Aid for Scientific Research C2-22591715 in
Japan
*Title Page (complete with Author details)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
Abstract
Objective: To investigate whether post-ischemic administration of minocycline attenuates
hind-limb motor dysfunction and gray and white matter injury after spinal cord ischemia.
Design: A prospective, randomized laboratory investigation
Setting: Laboratory in university, single-institutional
Parcitipants: Male New Zealand White rabbits
Intervention: Spinal cord ischemia was induced by an occlusion of infrarenal aorta for 15
min. Group M1 (n=8) with a minocycline administration 1 hour after reperfusion; Group
M3 (n=8) with a minocycline administration 3 hours after reperfusion; Group C (n=8) with
a saline administration 1 hour after reperfusion or Sham group (n=4). Minocycline was
intravenously administered at 10 mg/kg a total of 6 times at 12-hour intervals until 60 hours
after the initial administration.
Measurement and Main results: Hind limb motor function was assessed using Tarlov
score. For histological assessments, gray and white matter injury was evaluated 72 hours
after reperfusion using the number of normal neurons and percentage areas of vacuolations,
respectively. The motor function 72 hours after reperfusion was significantly better in the
*Structured Abstract
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
Group M1 than in the Group C. The number of neurons in the anterior horn was
significantly higher in the Group M1 than in the Group M3 or C, but did not significantly
differ between Groups M3 and C. No significant difference was noted in the percentage
areas of vacuolations among the ischemia groups.
Conclusions: Minocycline administration beginning at 1hour after reperfusion improved
hind-limb motor dysfunction and attenuated gray matter injury in a rabbit spinal cord
ischemia model.
Key words: Minocycline, ischemic spinal cord injury, reperfusion, neuroprotective effect,
rabbit
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
1
Introduction
An important complication of thoracic or thoracoabdominal aortic aneurysm is lower limb
paralysis due to spinal cord ischemia (SCI)(1, 2). Hypothermia therapy, spinal cord drainage,
and various drug therapies to protect the spinal cord from ischemia have been reported (3, 4),
but their effects are limited. Therefore, further efforts to clarify the mechanisms of nerve
injury and develop neuroprotective drugs are being made.
Minocycline is a semi-synthetic tetracycline antibiotic that passes the blood-brain barrier and
enters the central nervous system, and is noted for its biological other than antibiotic actions
(5-8). It has been reported to reduce the size of ischemic foci using brain ischemia models
(9-12). On the basis of these reports, an open-label trial was conducted in acute stroke patients,
showing a more favorable outcome compared with the placebo group (13). In spinal cord
injury models, minocycline has been shown to alleviate the impairment of spinal cord tissue
and improve motor functions in contusion and compression models (14-17).
Our previous study indicated that intraperitoneal administration of minocycline before
*Revised Manuscript
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
2
ischemia improved the hind limb motor function and alleviated impairment of the gray and
white matter in a rat SCI model (18). However, there are no data available on
minocycline-mediated neuroprotection when administered after reperfusion in a model of SCI.
The present study was conducted to examine whether minocycline administration after
reperfusion also has a neuroprotective effect in a rabbit model of SCI, and evaluated the
therapeutic window period of this effect.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
3
Methods
This study was approved by the Animal Experiment Committee of Nara Medical University
(Kashihara, Nara, Japan). Twenty-eight New Zealand White rabbits weighing 2.7-3.0 kg were
used. These rabbits were housed under 12-hour light-dark cycles with free access to food and
water.
Animal allocation
The rabbits were randomly allocated to one of the following 4 groups: Control (C) group
(n=8), minocycline administration after 1 hour (M-1) group (n=8), minocycline
administration after 3 hours (M-3) group (n=8), or sham group (n=4). In the M-1 and C
groups, minocycline (Nichi-iko, Toyama, Japan) or normal saline was administered
intravenously every 12 hours from 1 hour after reperfusion for 60 hours (a total of 6 times). In
the M-3 group, minocycline was also administered every 12 hours for 60 hours, but the
administration was started 3 hours after reperfusion. The dose of minocycline was 10 mg/kg
(in 3 ml). The sham group was administered the same amount of normal saline employing the
same schedule as in the C group without aortic occlusion.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
4
Spinal cord ischemia
The rabbits were anesthetized in a plastic box using oxygen and 5% isoflurane. A catheter was
inserted into the auricular vein, and Ringer’s solution was administered at 10 ml/kg/h. The
auricular artery was cannulated, and the proximal arterial pressure was measured. After the
intravenous administration of fentanyl at 50 μg/kg, endotracheal intubation was carried out,
and artificial ventilation (Harvard Respirator 510: Summit Medical, MA) was performed
using 2-3.5% isoflurane, 30% oxygen, and air by adjusting the end-tidal carbon dioxide
pressure to 35-40 mmHg. The rectal temperature was monitored continuously, and it was
adjusted to 38-39C using an electric mat. For measurement of the distal arterial pressure and
blood sampling (blood gas and blood sugar analyses), the right femoral artery was exposed,
and an SP-55 catheter was inserted. A 50-mm flank incision at the left costal level was made
after infiltration of 1% lidocaine, and the aorta was exposed from the retroperitoneal cavity at
the left renal artery level. A silicone thread 1.5 mm wide was carefully placed around the aorta
immediately distal to the left renal artery, and both ends of the thread were passed through an
occluder tube. Prior to the induction of ischemia, 600 U of heparin was administered. The
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
5
aorta was occluded by tightening the thread using the tube, and occlusion was confirmed by
monitoring the distal pressure. After 15 minutes, aortic occlusion was released. After
reperfusion, all catheters were removed, and the wound was closed. Blood was sampled 10
minutes before aortic occlusion and 10 minutes after reperfusion. The blood pressure and
body temperature were measured 10 minutes before aortic occlusion, during the ischemia (7.5
minutes after aortic occlusion), and 10 minutes after reperfusion.
Neurological evaluation
The hind limbs of the rabbits were neurologically evaluated 24, 48 and 72 hours after
reperfusion by a blinded observer. Assessment was made using Tarlov scoring (19), which
consists of a five-point grading scale : 0 = paraplegic with no lower extremity function; 1 =
poor lower extremity function, weak antigravity movement only; 2 = some lower extremity
motor function with good antigravity strength but inability to draw leg under the body or hop;
3 = ability to draw legs under the body and hop but not normally; 4 = normal motor function.
Histological evaluation
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
6
Following the neurological evaluation after 72 hours, 50 mg/kg of thiopental was
administered intraperitoneally, and the animals were anesthetized deeply using 5% isoflurane.
After 1,000 ml of cold heparinized physiologic saline was infused transcardially, 500 ml of
4% paraformaldehyde in 0.1M PBS was administered. The lumbar spinal cord was removed,
immersed in paraformaldehyde for 2days, the L5 part was cut off, embedded in paraffin, and
sliced at a thickness of 3 μm for hematoxylin and eosin staining.
Gray matter injury was evaluated in terms of the number of normal neurons remaining in the
left anterior horn of the spinal cord. An observer not informed of the randomization results
counted normal neurons in an area of the left hemisphere anterior to the central canal of the
spinal cord under light microscopy (200). White matter injury was evaluated by examining
the ventral, ventrolateral, and lateral areas and calculating the percentage areas of vacuolation,
comprising the percentage of a 0.04-mm2 area occupied by vacuoles. Each area was divided
into 144 sub-areas using grid lines, a sub-area was regarded as a vacuolated area if 75% or
more of it was occupied by vacuoles, and the percentage of vacuolated sub-areas in the 144
sub-areas was calculated. The total percentage of areas of vacuolation was calculated as a
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
7
mean of the 3 areas on each side.
Statistical analysis
The physiologic variables, number of normal neurons, and percentage areas of vacuolation
were analyzed employing one-factor analysis of variance, and Fisher’s PLSD was used as a
post-hoc test. The motor function of the hind limbs was examined with the Kruskal-Wallis test,
and the Mann-Whitney U-test was used as a post-hoc test. P value less than 0.05 was
considered significant.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
8
Results
Physiological variables are shown in table 1. There were no significant differences in the body
weight or rectal temperature among the groups. Blood pressure values were similar among the
groups before aortic occlusion, however, were significantly higher in the sham group than the
ischemic groups during ischemia. Blood gas data are shown in table 2. No significant
difference was noted in any of the blood test items including the pH, PaCO2, PaO2, hematocrit,
and blood glucose level among the groups.
Tarlov Scores 24, 48 and 72 hours after reperfusion were shown in table 3. Figure 1 shows the
individual neurologic scores 72 hours after reperfusion. Tarlov Scores in the sham group were
significantly higher compared with those in the 3 groups exposed to ischemia. Tarlov Scores
72 hours after reperfusion were significantly higher in the M-1 group compared with those in
the control group. No significant differences in Tarlov Score were noted between the C and
M-3 groups.
Histograms of the numbers of neurons per animal and representative photomicrographs of
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
9
hematoxyline and eosin-stained section were shown in figure 1 and 2, respectively. The
numbers of normal neurons were shown in figure 3. The number of normal neurons was
significantly higher in the sham group than those in the other 3 groups. The number of normal
neurons in the M-1 group was significantly higher than those in the control group. There were
no significant differences in the number of normal neurons between the C and M-3 groups.
Figure 4 shows the total percentage areas of vacuolation in each group . Percentage areas of
vacuolation in the C group were significantly higher than in the sham group. While no
significant differences were noted among the 3 groups exposed to ischemia, the percentage
areas of vacuolation were lower in the M-1 group than in the C group.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
10
Discussion
The results in the present study showed that intravenous administration of minocycline for 3
days at an interval of 12 hours, beginning at 1 hour, but not 3 hours, after reperfusion,
significantly improved the hind limb motor function and significantly increased the number of
normal neurons in the anterior horn 72 hours after reperfusion in rabbits subjected to spinal
cord ischemia for 15 min, while the percentage areas of vacuolation were not affected by the
administration of minocycline. These results suggest that minocycline administration after
reperfusion can be neuroprotective, but early initiation of administration would be necessary
for the treatment to be effective.
Although there has been no data available regarding the post-ischemic administration of
minocycline in a model of spinal cord ischemia, neuroprotective effects of minocycline have
been shown in models of cerebral ischemia (9-11, 20). Yrjänheikki et al. (9) reported that
intraperitoneal administration of minocycline, beginning at 12 hours before ischemia or 30
minutes after reperfusion increased the number of remaining CA1 pyramidal neurons in a rat
model of global cerebral ischemia. They also reported that monocycline administration,
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
11
beginning at 12 hours before ischemia or 4 hours after reperfusion significantly decreased the
infarct volume after middle cerebral artery occlusion in rats (10).
Regarding the effects of minocycline on SCI, our previous report (18) in a rat aortic occlusion
model is the first to our knowledge. We administered minocycline intraperitoneally at 45
mg/kg at an interval of 12 hours before ischemia, and reported the alleviation of impairment
of the hind limb motor function and white and gray matter injury after 72 hours. The results in
the present study indicated a neuroprotective effect of minocycline, which was administered 1
hrs, but not 3 hrs, after reperfusion in a rabbit model of SCI.
In the present study, a rabbit model of SCI was used due to the following reasons. First, in a
rat SCI model, it has been reported that motor function gradually improved without no
delayed deterioration, while hind-limb motor function deteriorated after SCI over 2 weeks in a
rabbit model (21). Delayed development of paraplegia is well known in human, so that the
time course after SCI in human may resemble to that in rabbit. Second, peritoneal
administration is not appropriate for further clinical application and for accurate assessment of
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
12
therapeutic window due to variation in the absorption rate (5, 8). Repetitive intravenous
administration could be performed if a rabbit model was used.
The dosage of minocycline in the present study was determined in the following reasons. The
blood level of minocycline is considered to be similar after intravenous administration at 20
mg/kg and intraperitoneal administration at 90 mg/kg in rats (8). Xu L et al. (11) reported that
the blood minocycline level on intravenous administration at 3 mg/kg in rats was equal to that
at 200 mg in humans, which is a standard dose for humans. In the present study, we set the
dose for intravenous administration at 10 mg/kg every 12 hours on the basis of the dose used
in rabbits in expectation of an antibiotic effect (6 mg/kg, i.v., every 8 hours) (22). As a result,
intravenous administration of minocycline at this dosage for 3 days at an interval of 12 hours,
beginning at 1 hour, but not 3 hours, after reperfusion, significantly improved neurological
outcome and alleviated gray matter injury 72 hours after reperfusion.
Although exact mechanisms of minocycline-mediated neuroprotective effects in this study are
unknown, possible mechanisms may include anti-inflammatory actions due to the suppression
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
13
of microglia activation and subsequently decreasing the release of cytokines and chemokines
(10,15,23-25), anti-apoptotic actions (26,27) due to inhibition of cytochrome C release(17)
and caspase expression (28,29), inhibition of proNGF (Nerve growth factor) production (30),
prevention of toxicity of glutamic acid (10), suppression of NO synthetase (22), and
inhibitions of p38MAPK activation in microglia (22, 25, 30). However, since we did not
perform the study to clarify the mechanisms of minocycline-mediated neuroprotection, further
studies would be required.
There are several limitations in this study. First, concerning the dose, minocycline might also
have been effective in the M-3 group if it had been administered at a higher dose or different
regime for administration. Second, concerning the severity of ischemia, the results may have
changed depending on the severity of SCI. However, the data of our previous studies
indicated that 13-15 minutes time of ischemia is appropriate to evaluate the effect of
neuroprotection. Aortic clamping for more than 20 minutes is too severe to destroy the spinal
cord tissue. Third, the group in which minocycline was administered before ischemia, was not
included in this study. So it is unclear whether administration of minocycline before ischemia
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
14
is more effective than that after reperfusion. Fourth, regarding the white matter injury, the
evaluation at more than 4 days but not 72 hours after reperfusion might be appropriate. Kurita
et al. (21) reported that white matter injury was unclear 24 hours after reperfusion but became
clear after 4 days in a rabbit SCI model. Fifth, demonstration of neuroprotection in animal
species does not necessarily translate to humans. Finally, concerning the long-term outcome,
evaluation of the motor function and histological changes after a long-term interval after
reperfusion would be necessary.
In summary, the effects of the intravenous administration of minocycline on white and gray
matter injury and motor function were evaluated in a rabbit 15-min SCI model. As a result, an
improvement in the motor function and alleviation of gray matter injury were observed after
72 hours when the drug was administered 1 hour after ischemia, but not when it was
administered after 3 hours. Since minocycline is widely used clinically as an antibiotic,
sufficient evaluation of its use as a drug for the prevention of paraplegia associated with
surgery for thoracoabdominal aortic aneurysm is justified. While further evaluation would be
necessary concerning its safe and effective use, its administration early after the onset of
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
15
ischemia may be one of alternative strategies to prevent further development of ischemic
spinal cord injury.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
16
References
1) Coselli JS. The use of left heart bypass in the repair of thoracoabdominal aortic
aneurysms: current techniques and results. Semin Thoracic Cardiovasc Surg 15: 326-32,
2003
2) Safi HJ, Estrera AL, Miller CC, Huynh TTT, Porat EE Azizzadeh A, Meade R,
Goodrick JS. Evolution of risk for neurologic deficit after descending and
thoracoabdominal aortic repair. Ann Thoracic Surg 80: 2173-9, 2005
3) Horiuchi T, Kawaguchi M, Kurita N, Inoue S, Nakamura M, Konishi N, Furuya H. The
long-term effects of mild to moderate hypothermia on gray and white matter injury after
spinal cord ischemia in rats. Anesth Analg 109(2): 559-66, 2009
4) Horiuchi T, Kawaguchi M, Sakamoto T, Kurita N, Inoue S, Nakamura M, Konishi N,
Furuya H. The effects of the delta-opioid agonist SNC80 on hind-limb motor function
and neuronal injury after spinal cord ischemia in rats. Anesth Analg 99(1): 235-40, 2004
5) Yong VW, Wells J, Giuliani F, Casha S, Power C, Mets LM. The promise of
minocycline in neurology. Lancet Neurol 3: 744-751, 2004
6) Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
17
neuroprotection. Pharmacotherapy 26: 515-521, 2006
7) Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behavioral Brain
Research 196: 168-179, 2009
8) Fagan SC, Edwards DJ, Borlongan CV, Xu L, Arora A, Feuerstein G, Hess DC. Optimal
delivery of minocycline to the brain: implication for human studies of acute
neuroprotection. Exp Neurol 186: 248–51, 2004
9) Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. Tetracyclines inhibit
microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad
Sci U S A. 95(26): 15769-74, 1998
10) Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J. A
tetracycline derivative, minocycline, reduces inflammation and protects against focal
cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A. 96(23):
13496-500, 1999
11) Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G,
Hess DC. Low dose intravenous minocycline is neuroprotective after middle cerebral
artery occlusion-reperfusion in rats. BMC Neurol. 4: 7, 2004
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
18
12) Hewlett KA, Corbett D. Delayed minocycline treatment reduces long-term functional
deficits and histological injury in a rodent model of focal ischemia. Neuroscience.
141(1): 27-33, 2006
13) Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz
M, Sadeh M. Minocycline treatment in acute stroke: an open-label, evaluator-blinded
study. Neurology 69(14): 1404-10, 2007
14) Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline
facilitates significant recovery from spinal cord injury in mice. Brain 126(Pt 7): 1628-37,
2003
15) Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH.
Minocycline reduces cell death and improves functional recovery after traumatic spinal
cord injury in the rat. J Neurotrauma 20(10): 1017-27, 2003
16) Saganová K, Orendácová J, Cízková D, Vanický I. Limited minocycline neuroprotection
after balloon-compression spinal cord injury in the rat. Neurosci Lett 433(3): 246-9,
2008
17) Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, Woodard EJ, Snyder EY,
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
19
Eichler ME, Friedlander RM. Minocycline inhibits contusion-triggered mitochondrial
cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl
Acad Sci U S A. 101(9): 3071-6, 2004
18) Takeda M, Kawaguchi M, Kumatoriya T, Horiuchi T, Watanabe K, Inoue S, Konishi N,
Furuya H. Effects of minocycline on hind-limb motor function and gray and white
matter injury after spinal cord ischemia in rats. Spine 36(23): 1919-24, 2011
19) Tarlov IM. Spinal cord compression: Mechanisms of paralysis and treatment. Springfield,
Illinois: Charles C Thomas, 1957
20) Liu Z, Fan Y, Won SJ, Neumann M, Hu D, Zhou L, Weinstein PR, Liu J Chronic
treatment with minocycline preserves adult new neurons and reduces functional
impairment after focal cerebral ischemia. Stroke 38(1): 146-52, 2007
21) Kurita N, Kawaguchi M, Kakimoto M, Yamamoto Y, Inoue S, Nakamura M, Konishi N,
Patel PM, Furuya H. Reevaluation of gray and white matter injury after spinal cord
ischemia in rabbits. Anesthesiology 105: 305-12, 2006
22) Nicolau DP, Freeman CD, Nightingale CH, Quintiliani R. Pharmacokinetics of
minocycline and vancomycin in rabbits. Lab Anim Sci. 43(3): 222-5, 1993
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
20
23) Hayakawa K, Mishima K, Nozako M, Hazekawa M, Mishima S, Fujioka M, Orito K,
Egashira N, Iwasaki K, Fujiwara M. Delayed treatment with minocycline ameliorates
neurologic impairment through activated microglia expressing a high-mobility group
box1-inhibiting mechanism. Stroke 39: 951-958, 2008
24) Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a
tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation
and proliferation of microglia. J Neurosci 21: 2580-2588, 2001
25) Lee YL, Shih K, Bao P, Ghirnikar RS, Eng LF. Cytokine chemokine expression in
contused rat spinal cord. Neurochem Int. 36(4-5): 417-25, 2000
26) Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to
blood-brain barrier constituents. Improvement by minocycline in vivo and in vitro.
Stroke 37: 1087-1093, 2006
27) Tang XN, Wang Q, Koike MA, Cheng D, Goris ML, Blankenberg FG, Yenari MA.
Monitoring the protective effects of minocycline treatment with radiolabeled annexin V
in an experimental model of focal cerebral ischemia. J Nucl Med. 48(11): 1822-8, 2007
28) David P. Stirling, Kourosh Khodarahmi, Jie Liu, Lowell T. McPhail, Christopher B.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
21
McBride, John D. Steeves, Matt S. Ramer, and Wolfram Tetzlaff. Minocycline Treatment
Reduces Delayed Oligodendrocyte Death, Attenuates Axonal Dieback, and Improves
Functional Outcome after Spinal Cord Injury. The Journal of Neuroscience, 24(9):
2182–2190, 2004
29) Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic
brain injury-mediated caspase-1 activation, tissue damage, and neurological
dysfunction. Neurosurgery. 48(6): 1393-9, 2001
30) Yune TY, Lee JY, Jung Gy, Kim SJ, Jiang MH, Kim YC, Oh YJ, Markelonis GJ, Oh TH.
Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor
production in microglia after spinal cord injury. J Neurosci 27(29): 7751-61, 2007
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
22
Figure legends
Figure 1
Histograms of the Tarlov score after 72 hours and the numbers of neurons per animal
in the sham, control (C), minocycline administration after 1 hour (M-1), and minocycline
administration after 3 hours (M-3) groups.
Figure 2
Representative photomicrographs of hematoxylin and eosin-stained section in the
anterior horn of the spinal cord in the sham (a), the control (b), the M-1 (c), and the M-3 (d)
groups. Normal neurons were better preserved in the M-1 group compare with those in the
control and the M-3 groups.
Figure 3
The numbers of normal neurons in the sham, control (C), minocycline administration
after 1 hour (M-1), and minocycline administration after 3 hours (M-3) groups. Of the 3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
23
groups exposed to ischemia, the number of remaining neurons was higher in the M-1 group
than in the other 2 groups (p<0.05).
Figure 4
The total percentage areas of vacuolation in the sham, control (C), minocycline
administration after 1 hour (M-1), and minocycline administration after 3 hours (M-3) groups.
It was significantly higher only in the C group than in the sham group (P<0.05). No
significant difference was noted among the 3 groups exposed to ischemia.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
Table 1. Physiological variables
Sham C M-1 M-3
(n=4) (n=8) (n=8) (n=8)
Weight (kg) 2.9±0.1 2.8±0.1 2.8±0.1 2.9±0.1
Mean arterial pressure
(mmHg)
Before 67±7 63±5 60±11 65±7
During 66±10 12±2 a 12±1 a 12±1 a
After ND 54±10 52±7 57±4
Rectal temperature (℃)
Before 38.7±0.2 38.6±0.4 38.5±0.3 38.6±0.3
During 38.3±0.3 38.7±0.3 38.5±0.2 38.7±0.3
After 38.4±0.4 38.6±0.3 38.7±0.3 38.5±0.2
Data are expressed as mean±SD. ND; no data.
Mean arterial pressure and rectal temperature were measured 10 minutes before aortic
occlusion (before), during ischemia (7.5 minutes after aortic occlusion) (during) and 10
minutes after reperfusion (after).
a; P<0.05 vs. Sham.
Table 1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
Table 2. Blood gas data
Sham C M-1 M-3
(n=4) (n=8) (n=8) (n=8)
pH
Before 7.49±0.04 7.46±0.05 7.50±0.07 7.4±0.05
After 7.46±0.01 7.44±0.06 7.45±0.05 7.4±0.04
PaCO2 (mmHg)
Before 37±4 38±3 36±3 37±4
After 30±3 36±6 35±4 35±3
PaO2 (mmHg)
Before 160±44 159±31 154±30 134±30
After 195±16 171±33 164±28 152±23
Hematocrit (%)
Before 36±4 34±2 35±3 37±3
After 33±3 33±2 33±2 35±3
Glucose (mg/dl)
Before 116±22 123±18 137±28 138±23
After 151±19 160±45 139±44 142±32
Data are expressed as mean±SD. Blood gas data. Blood was sampled 10 minutes before
aortic occlusion (before) and 10 minutes after reperfusion (after). There were no
significant differences among the groups. PaCO2 and PaO2; arterial patial pressure of
carbon dioxide and oxygen, respectively.
Table 2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
Table 3. Neurological outcome
Tarlov score
Sham C M-1 M-3
(n=4) (n=8) (n=8) (n=8)
24 hrs 4 2.5 a 3 a 2 a
(4-4) (2-3) (3-3.25) (2-2)
48hrs 4 2 a 3 a 2 a
(4-4) (2-2) (2-3) (2-2)
72hrs 4 2 a 3 a,b 2 a
(4-4) (2-2) (2-3) (2-2)
Data are expressed as median (25th-75th). a; P<0.05 vs. Sham, b; P<0.05 vs. C.
Tarlov score: 0 = paraplegic with no lower extremity function; 1 = poor lower extremity function,
weak antigravity movement only; 2 = some lower extremity motor function with good antigravity
strength but inability to draw leg under the body or hop; 3 = ability to draw legs under the body and
hop but not normally; 4 = normal motor function.
Table 3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
0 1 2 3 4 0 10 20 30 Tarlov Score
Sham
Control
M-1
M-3
Figure 1
Normal Neurons
Figure 1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
Figure 2 Figure 2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
0
5
10
15
20
25
30
sham C M-1 M-3
Num
bar
of
Norm
al N
euro
ns
P < 0.05
Figure 3
(mean ± SD)
:p<0.05 vs sham
Figure 3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
0
1
2
3
4
5
6
7
8
sham C M-1 M-3
% A
rea
of
Vac
uola
tion
(mean ± SD)
Figure 4
:p<0.05 vs sham
Figure 4